TY - JOUR
T1 - Evaluating risk to people with epilepsy during the COVID-19 pandemic
T2 - Preliminary findings from the COV-E study
AU - Thorpe, Jennifer
AU - Ashby, Samantha
AU - Hallab, Asma
AU - Ding, Ding
AU - Andraus, Maria
AU - Dugan, Patricia
AU - Perucca, Piero
AU - Costello, Daniel
AU - French, Jacqueline A.
AU - O'Brien, Terence J.
AU - Depondt, Chantal
AU - Andrade, Danielle M.
AU - Sengupta, Robin
AU - Delanty, Norman
AU - Jette, Nathalie
AU - Newton, Charles R.
AU - Brodie, Martin J.
AU - Devinsky, Orrin
AU - Helen Cross, J.
AU - Sander, Josemir W.
AU - Hanna, Jane
AU - Sen, Arjune
N1 - Funding Information:
PP is supported by the National Health and Medical Research Council (APP1163708), the Epilepsy Foundation, the Royal Australasian College of Physicians, Melbourne Health, and Monash University. DMA is supported by EpLink, Dravet Syndrome Foundation, McLaughlin grants. NJ is the Bludhorn Professor of International Medicine and receives grant funding from NINDS (NIH U24NS107201, NIH IU54NS100064) and PCORI. JHC is supported by the National Institute of Health Research (NIHR) Biomedical Research Centre at Great Ormond Street Hospital, NIHR, Engineering and Physical Sciences Research Council, GOSH Charity, Epilepsy Research UK, and the Waterloo Foundation. JWS is based at UCLH/UCL Comprehensive Biomedical Research Centre, which receives a proportion of funding from the UK Department of Health's NIHR Biomedical Research Centres funding scheme. He receives support from the Dr Marvin Weil Epilepsy Research Fund, the Christelijke Vereniging voor de verpleging van Lijders aan Epilepsie, The Netherlands, and the UK Epilepsy Society. AS is supported by the Oxford NIHR Biomedical Research Centre at the John Radcliffe Hospital, UK.
Funding Information:
This study was funded by SUDEP Action Registered charity 1164250 (England & Wales) and supported by the Oxford NIHR Biomedical Research Centre. Conflicts of interest: The authors declare no direct conflicts of interest in relation to this work. We are grateful to all of the following organizations, and many individuals whom we are unable to name individually, for promoting this work through online platforms. We also very much appreciate the valuable input of all the respondents who have completed the surveys. BAND Foundation. Dravet Syndrome UK. Epilepsy Action. Epilepsy Connections. Epilepsy Foundation America. Epilepsy Research UK. Epilepsy Society. Epilepsy Sparks. IBE. ILAE ? British Branch. Matthew's Friend. Neurological Alliance. SUDEP Action. PP is supported by the National Health and Medical Research Council (APP1163708), the Epilepsy Foundation, the Royal Australasian College of Physicians, Melbourne Health, and Monash University. DMA is supported by EpLink, Dravet Syndrome Foundation, McLaughlin grants. NJ is the Bludhorn Professor of International Medicine and receives grant funding from NINDS (NIH U24NS107201, NIH IU54NS100064) and PCORI. JHC is supported by the National Institute of Health Research (NIHR) Biomedical Research Centre at Great Ormond Street Hospital, NIHR, Engineering and Physical Sciences Research Council, GOSH Charity, Epilepsy Research UK, and the Waterloo Foundation. JWS is based at UCLH/UCL Comprehensive Biomedical Research Centre, which receives a proportion of funding from the UK Department of Health's NIHR Biomedical Research Centres funding scheme. He receives support from the Dr Marvin Weil Epilepsy Research Fund, the Christelijke Vereniging voor de verpleging van Lijders aan Epilepsie, The Netherlands, and the UK Epilepsy Society. AS is supported by the Oxford NIHR Biomedical Research Centre at the John Radcliffe Hospital, UK.
Funding Information:
This study was funded by SUDEP Action Registered charity 1164250 (England & Wales) and supported by the Oxford NIHR Biomedical Research Centre.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/2
Y1 - 2021/2
N2 - The COVID-19 pandemic has caused global anguish unparalleled in recent times. As cases rise, increased pressure on health services, combined with severe disruption to people's everyday lives, can adversely affect individuals living with chronic illnesses, including people with epilepsy. Stressors related to disruption to healthcare, finances, mental well-being, relationships, schooling, physical activity, and increased isolation could increase seizures and impair epilepsy self-management. We aim to understand the impact that COVID-19 has had on the health and well-being of people with epilepsy focusing on exposure to increased risk of seizures, associated comorbidity, and mortality. We designed two online surveys with one addressing people with epilepsy directly and the second for caregivers to report on behalf of a person with epilepsy. The survey is ongoing and has yielded 463 UK-based responses by the end of September 2020. Forty percent of respondents reported health changes during the pandemic (n = 185). Respondents cited a change in seizures (19%, n = 88), mental health difficulties (34%, n = 161), and sleep disruption (26%, n = 121) as the main reasons. Thirteen percent found it difficult to take medication on time. A third had difficulty accessing medical services (n = 154), with 8% having had an appointment canceled (n = 39). Only a small proportion reported having had discussions about epilepsy-related risks, such as safety precautions (16%, n = 74); mental health (29%, n = 134); sleep (30%, n = 140); and Sudden Unexpected Death in Epilepsy (SUDEP; 15%, n = 69) in the previous 12 months. These findings suggest that people with epilepsy are currently experiencing health changes, coupled with inadequate access to services. Also, there seems to be a history of poor risk communication in the months preceding the pandemic. As the UK witnesses a second COVID-19 wave, those involved in healthcare delivery must ensure optimal care is provided for people with chronic conditions, such as epilepsy, to ensure that avoidable morbidity and mortality is prevented during the pandemic, and beyond.
AB - The COVID-19 pandemic has caused global anguish unparalleled in recent times. As cases rise, increased pressure on health services, combined with severe disruption to people's everyday lives, can adversely affect individuals living with chronic illnesses, including people with epilepsy. Stressors related to disruption to healthcare, finances, mental well-being, relationships, schooling, physical activity, and increased isolation could increase seizures and impair epilepsy self-management. We aim to understand the impact that COVID-19 has had on the health and well-being of people with epilepsy focusing on exposure to increased risk of seizures, associated comorbidity, and mortality. We designed two online surveys with one addressing people with epilepsy directly and the second for caregivers to report on behalf of a person with epilepsy. The survey is ongoing and has yielded 463 UK-based responses by the end of September 2020. Forty percent of respondents reported health changes during the pandemic (n = 185). Respondents cited a change in seizures (19%, n = 88), mental health difficulties (34%, n = 161), and sleep disruption (26%, n = 121) as the main reasons. Thirteen percent found it difficult to take medication on time. A third had difficulty accessing medical services (n = 154), with 8% having had an appointment canceled (n = 39). Only a small proportion reported having had discussions about epilepsy-related risks, such as safety precautions (16%, n = 74); mental health (29%, n = 134); sleep (30%, n = 140); and Sudden Unexpected Death in Epilepsy (SUDEP; 15%, n = 69) in the previous 12 months. These findings suggest that people with epilepsy are currently experiencing health changes, coupled with inadequate access to services. Also, there seems to be a history of poor risk communication in the months preceding the pandemic. As the UK witnesses a second COVID-19 wave, those involved in healthcare delivery must ensure optimal care is provided for people with chronic conditions, such as epilepsy, to ensure that avoidable morbidity and mortality is prevented during the pandemic, and beyond.
KW - Chronic illness
KW - Coronavirus
KW - Mental health
KW - SUDEP
KW - Seizures
UR - http://www.scopus.com/inward/record.url?scp=85099398207&partnerID=8YFLogxK
U2 - 10.1016/j.yebeh.2020.107658
DO - 10.1016/j.yebeh.2020.107658
M3 - Article
C2 - 33341393
AN - SCOPUS:85099398207
SN - 1525-5050
VL - 115
JO - Epilepsy and Behavior
JF - Epilepsy and Behavior
M1 - 107658
ER -